齐拉西酮与利培酮治疗精神分裂症疗效的Meta分析  

META-ANALYSIS OF THE EFFECTIVENESS OF ZIPRASIDONE AND RISPERIDONE IN TREATMENT OF SCHIZOPHRENIA

作　　者：姜倩[1] 吴艳乔[2] 

机构地区：[1]四川大学华西公共卫生学院卫生统计教研室,成都610041 [2]四川大学华西妇女儿童医院

出　　处：《现代预防医学》2009年第4期601-603,605,共4页Modern Preventive Medicine

摘　　要：[目的]比较国内齐拉西酮与利培酮治疗精神分裂症疗效。[方法]采用Review Manager4.2分析软件,对国内11篇有关齐拉西酮与利培酮治疗精神分裂症疗效的研究结果进行固定效应模型的Meta分析。[结果]齐拉西酮治疗精神分裂症的总显效率和总有效率均与利培酮组无差别,合并RR分别为0.96和0.95,95%可信区间分别为0.87～1.05和0.90～1.00。[结论]齐拉西酮与利培酮治疗精神分裂症患者疗效相当,其不良反应小,是一种安全有效的新型抗精神分裂症药物。[ Objective] To compare the effectiveness of ziprasidone and risperidone in treatment of schizophrenia. [ Methods] The results of 11 studies about effeettveness of ziprasidone and risperidone in treatment of schizophrenia in China were analyzed by Review Manager 4.2 and the fixed effect model of recta-analysis method was used. [ Results] Both total marked improvement rate and total effective rate did not found significant difference between the two groups. Pooled RR of total marked improvement rate and total effective rate were 0.96 and 0.95, respectively, of which the 95% confidence intervals were 0.87-1.05 and 0.90-1.00, respectively. [Conclusion] Prasidone and risperidone with less adverse effect are safe and have good effect in treatment of schizophrenia.

关 键 词：齐拉西酮 利培酮 精神分裂症 META分析 

分 类 号：R749.5[医药卫生—神经病学与精神病学]